Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

embed
 plays        
How to Play
HintAnswer
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)
Boceprevir Class
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
MOA: An adenosine analogue. Structurally similar to adefovir.
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
PEG-IFN α-2a/2b class
Entecavir (Baraclude) Class
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
Lamivudine (3TC, Heptovir) Class
Use: Lamivudine-resistant HBV. Adults only
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
PEG-IFN α-2a Class
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
MOA: A thymidine analog
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
Group P-kinetics: Pills once a day for a year or longer
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
MOA: A cytosine analogue
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
Use: The most potent anti-HBV agent. Adults only
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction
P-kinetics: Synthetic (consensus). SC
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
HintAnswer
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
P-kinetics: Natural. SC or IM
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
Use: HBV treatment adults only
Tenofovir Class
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
IFN α-2b Class
IFN alfacon-1 class
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
Telbivudine (Tyzeka) Class
IFN α-2a/2b class
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
Telaprevir Class
Drug MOA: PEG = polyethylene glycol
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
Adefovir dipivoxil (Hepsera) Class

Friend Scores


  Player Best Score Plays Last Played
You You haven't played this game yet.

You Might Also Like...

Extras

Created Feb 10, 2012ReportNominate
Tags:agent